Home > Insider Trading > Filing (0000903423-14-000416)

Filing Details

Accession Number:: 0000903423-14-000416
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-07-11 16:31:20
Reporting Period:: 2014-07-09

Filing Date:: 2014-07-11
Accepted Time:: 2014-07-11 16:31:20
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1337553	Aerie Pharmaceuticals Inc	AERI	Biological Products, (No Disgnostic Substances) (2836)	203109565

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
860866	David Bonderman	C/O Tpg Global, Llc 301 Commerce Street, Suite 3300 Fort Worth TX 76102	No	No	Yes	No
1099776	G James Coulter	C/O Tpg Global, Llc 301 Commerce Street, Suite 3300 Fort Worth TX 76102	No	No	Yes	No
1495741	Tpg Group Holdings (Sbs) Advisors, Inc.	C/O Tpg Global, Llc 301 Commerce Street, Suite 3300 Fort Worth TX 76102	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2014-07-09	500,000	$25.05	3,887,466	No	4	S	Indirect	See Explanation of Responses
Common Stock	Disposition	2014-07-10	500,000	$25.28	3,387,466	No	4	S	Indirect	See Explanation of Responses

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Explanation of Responses
No	4	S	Indirect	See Explanation of Responses

Footnotes

On July 9, 2014, TPG Biotechnology Partners, L.P. ("TPG Biotechnology") and TPG Biotech Reinvest AIV, L.P. ("TPG Biotech Reinvest" and, together with TPG Biotechnology, the "TPG Funds") sold an aggregate of 500,000 shares of Common Stock ("Common Stock") of Aerie Pharmaceuticals, Inc. (the "Issuer"), pursuant to Rule 144 ("Rule 144") under the Securities Act of 1933, as amended.
On July 10, 2014, TPG Biotechnology and TPG Biotech Reinvest sold an aggregate of 500,000 shares of Common Stock pursuant to Rule 144.
The number of securities reported represents an aggregate number of shares of Common Stock sold in multiple open market transactions over a range of sale prices. The price reported represents the weighted average price. Sale prices ranged from $25.28 to $25.82 per share, inclusive. The Reporting Persons undertake to provide the staff of the Securities and Exchange Commission, the Issuer or a stockholder of the Issuer, upon request, the number of shares of Common Stock sold by the Reporting Persons at each separate price within the range.
David Bonderman and James G. Coulter are officers and sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. ("Group Advisors" and, together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnology GenPar Advisors, LLC, which is the general partner of TPG Biotechnology GenPar, L.P., which is the general partner of each of TPG Biotechnology, which directly holds 2,743,154 shares of Common Stock, and TPG Biotech Reinvest, which directly holds 644,312 shares of Common Stock.
Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each Reporting Person and each of the TPG Funds disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's or such TPG Fund's pecuniary interest therein, if any.
Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.